RxDoctor Payments DataLook up a doctor →

Rita Zuber, NP

Nurse Practitioner · West Monroe, LANPI 1720038003

Payments from drug & device makers

$9,002in general payments, 2019–2025

Across 581 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$912
  • Lilly USA, LLC$862
  • Esperion Therapeutics, Inc.$534
  • Bayer$422
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,89699%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,002 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$104,721
Medicare patients
320
Services billed
3,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide169$179,382
EliquisApixaban117$82,053
JardianceEmpagliflozin46$54,720
JanuviaSitagliptin Phosphate61$50,642
OzempicSemaglutide32$40,592
KerendiaFinerenone24$28,808
EntrestoSacubitril/Valsartan21$23,086
TrulicityDulaglutide16$17,581
FarxigaDapagliflozin Propanediol19$13,802
NexlizetBempedoic Acid/Ezetimibe30$13,093
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$10,611
LinzessLinaclotide19$9,777
Repatha SureclickEvolocumab16$8,782
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,590
XiidraLifitegrast11$7,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$862$196,963185 claims
PfizerEliquis$245$82,053117 claims
Boehringer IngelheimJardiance$247$54,72046 claims
MerckJanuvia$29$50,64261 claims
Novo NordiskOzempic$912$40,59232 claims
BayerKerendia$422$28,80824 claims
NovartisEntresto$15$23,08621 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$534$18,86445 claims
AbbVieLinzess, Synthroid$1,597$13,836100 claims
AstraZenecaFarxiga$1,226$13,80219 claims
GSKTrelegy Ellipta$191$7,59012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in West Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →